Transformational
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
Disease-Modifying
Advances in the Treatment
of Keratoconus & Myopia
About iVeena
iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first in class, investigational eyedrop formulation for pediatric myopia.
What We Do
Lead programs comprise of novel proprietary eye drops; IVMED-85 for myopia and IVMED-80 (granted ODD) for keratoconus.
News
February 4th 2026
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company advancing innovative pharmacologic therapies for refractive eye diseases, today announ
June 2nd 2025
iVeena Announces IND Submission to the U.S. FDA for a Phase 2 Clinical Trial for Pediatric Myopia
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced the submission of an Inv
February 5th 2025
iVeena Secures $3 Million in Series B-2 Financing to Accelerate Development of IVMED-85 for Myopia
SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a biopharmaceutical company advancing IVMED-85 for the treatment of pediatric myopia, today announced that it has closed its f